Explore /
Poster
/ A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Authors

Aaron James Scott

University of Colorado, Denver, Aurora, CO

Aaron James Scott , Bert H. O'Neil , Christina Gomes , Joaquina Celebre Baranda , Steven J. Cohen , Mohamedtaki Abdulaziz Tejani , Robert T. Maguire , Francois Wilhelm , Manoj Maniar , Deirdre Jill Cohen , Wen Wee Ma , Dara Aisner , Jonathan K. Cho , Olugbenga Olanrele Olowokure , Andrew L. Coveler , Alex R. Menter , Peter Rubin , Mike Cusnir , Wells A. Messersmith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01360853

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 342)

DOI

10.1200/jco.2015.33.3_suppl.342

Abstract #

342

Poster Bd #

C11

Abstract Disclosures

Similar Posters

Poster

2015 ASCO Annual Meeting